Intellia Therapeutics - Steady Progress, Historic Commercial Approval In Sight
Source: SeekingAlpha
2026-05-31 08:45:00 ET
Intellia Therapeutics Investment Overview
In February I wrote a post for Seeking Alpha on the gene therapy-focused biotech Intellia Therapeutics ( NTLA ), titled "2 Major Catalysts Will Determine Stock's Trajectory In 2026." At the time of publication, Intellia stock traded at $11.1 per share, and at the time of writing, it is up >25%, trading at $14 per share, with a market cap valuation of $1.96bn....
Read the full article on Seeking Alpha
For further details see:
Intellia Therapeutics - Steady Progress, Historic Commercial Approval In Sight
Intellia Therapeutics Inc.
NASDAQ: NTLA
NTLA Trading
16.52% G/L:
$14.92 Last:
5,880,089 Volume:
$13.20 Open:
NTLA Latest News
June 03, 2026 12:25:00 pm
1 Sector Warren Buffett and Greg Abel Are Largely Ignoring -- and Why Investors Shouldn't
June 01, 2026 07:30:00 am
Intellia Therapeutics to Report Additional Phase 3 HAELO Data for Lonvoguran Ziclumeran (lonvo-z) in Late-Breaking Oral Presentation at EAACI 2026
May 11, 2026 07:30:00 am
Intellia Therapeutics Announces First Quarter 2026 Financial Results and Business Updates
April 29, 2026 07:00:00 am
Intellia Therapeutics Announces Pricing of Public Offering of Common Stock
NTLA Stock Data
$1,420,074,893
112,239,198
1.45%
105
N/A
Biotechnology & Life Sciences
Healthcare
US
Cambridge
